Compare AU
Compare CURE vs. RINC
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and RINC. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | RINC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 1 |
Median incremental investment | $619.50 | $1,094.28 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $170.43 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | RINC | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | RINC.AX was created on 2018-02-13 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide a pre-tax income yield above the S&P/ASX 200 Index and to grow this income above the rate of inflation. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | BetaShares Mrtn Currie Rl Inc Fund (Managed Fund) (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (67.74 %) New Zealand (11.82 %) United States (6.44 %) |
Management fee | 0.45 % | 0.85 % |
Key Summary
CURE | RINC | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | S&P ASX 200 |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.85 % |
Price | $49.94 | $8.97 |
Size | $38.065 million | $49.502 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 4.24 % | 4.14 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 19/02/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | RINC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 1 |
Median incremental investment | $619.50 | $1,094.28 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $170.43 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | RINC | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | RINC |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |